Renal osteodystrophy in diabetic patients. To assess the effects of diabetes mellitus on renal osteodystrophy, we examined the database of 256 patients (45% on hemodialysis and 55% on peritoneal dialysis) who were prospectively studied in three Toronto dialysis centers between October of 1987 and. All patients had serial documentation of their clinical, laboratory and risk parameters of bone disease, and completed a series of investigations that included the deferoxamine test, measurement of intact 1-84 PTH levels, and an iliac crest bone biopsy.
(46 vs. 31%; P = NS) tended to be more common in diabetic patients. The prevalence of aluminum bone disease was the same in both groups (27%). Diabetic patients ingested a smaller cumulative dose of aluminum gels (3.7 0.6 vs. 9.3 1.1 kg; P < 0.005), yet had a higher rate of aluminum accumulation on bone surfaces than non-diabetic patients Although the cumulative exposure to aluminum gels remained the major risk factor for aluminum bone disease (P < 0.0001), a positive interaction was noted for diabetic mellitus to increase this risk (P < 0.05). Thus, diabetes mellitus appears to predispose dialysis patients to low bone-turnover states. In addition, it appears to increase aluminum accumulation on bone surfaces and predisposes to aluminum bone disease. The clinical significance of the aplastic disorder remains to be defined.
Since the time when hemodialysis was first introduced for the treatment of end-stage renal disease (ESRD), many therapeutic advances have taken place. The introduction of continuous ambulatory peritoneal dialysis (CAPD) [1] , and the improved results in transplantation due to better surgical and medical management and the use of cyclosporin A [2] have given nephrologists greater flexibility in managing patients with ESRD. Concurrently, the patient composition selected for renal replacement treatment has changed significantly. 125% in Canada and by 450% in the USA. Thus, diabetic patients with nephropathy have now emerged as the single largest group on renal replacement therapy [3, 4] .
Previous studies have shown that patients with insulindependent diabetes mellitus and normal renal function have reduced bone mass, low bone formation rates and low parathyroid hormone levels when compared to age-matched normal subjects [5, 61 . In hemodialysis patients, those with diabetes mellitus have also been noted to have lower plasma parathyroid hormone levels and bone formation rates [7, 8] , as well as diminished parathyroid gland responsiveness to an acute hypocalcemic challenge [9] when compared to non-diabetic controls. Thus, it has been suggested that the diabetic state may predispose dialysis patients to low turnover bone lesions through its associated "relative" hypoparathyroidism [7] [8] [9] . However, since aluminum intoxication is also known to suppress parathyroid function [101, the interpretation of the above studies has been confounded by the possible co-existence of aluminum intoxication in many of the patients [7] [8] [9] . Recently, in a multivariant analysis based on a largely unselected group of dialysis patients, we have shown that diabetes mellitus is indeed a risk factor for low-turnover bone disorders independent of the effect of cumulative aluminum exposure and dialysis modality [11] . In the present study, we examined the potential modulating role of diabetes mellitus on uremic osteodystrophy.
Methods
The study design and organization of the Renal Osteodystrophy Study have been detailed previously [11] [12] [13] . It was a prospective, cross sectional study of renal bone disease.
Study design and data collection
In the Renal Osteodystrophy Study, we documented all the risk factors and events for bone disease in all study patients from the time of their initiation on dialysis, and throughout a two-year study period. Clinical parameters assessed included: musculoskeletal findings of proximal myopathy (tested at the time of bone biopsy), unexplained bone pain or pathological fracture(s), and unexplained neurological findings of ataxia, dyspraxia, seizure or dementia. Laboratory parameters assessed included serum total protein, albumin, calcium, phosphorus, alkaline phosphatase, hemoglobin, MCV and aluminum. Risk factors assessed included: patient age, sex, dialysis modality and duration, phosphate binder types and doses since initiation of dialysis, vitamin D treatment, and a history of: diabetes mellitus, failed renal transplant, parathyroidectomy and bilateral nephrectomy.
Special investigations
Parathyroid hormone (1-84 i-PTH). Plasma samples were assayed using an immunoradiometric assay (IRMA; Nichols Institute, California, USA) with specificity for intact PTH which does not detect carboxyl-terminal fragments (normal range for patients without renal failure: 1 to 5.5 pmol/liter or 10-55 pg/mI) [14] . All blood samples were collected prior to heparinization in hemodialysis patients.
Deferoxamine (DFO) test. A standard DFO dose of 40 mg/kg was injected i.v. in hemodialysis and i.p. in peritoneal dialysis patients, and pre-and post-DFO (drawn 36 to 48 hours post-DFO in hemodialysis and 18 to 24 hours post-DFO in peritoneal dialysis patients), and serum aluminum levels were collected using trace mineral tubes [15] . All aluminum-containing medications were discontinued 48 hours prior to pre-DFO aluminum sample, and were restarted only after the post-DFO aluminum level was sampled. All serum aluminum levels were measured using graphite furnace atomic absorption spectrophotometry with a normal reference range < 560 nM (100 nM = 2.7 pg/liter) [15] . Delta aluminum was defined as the incremental rise of serum aluminum level after DFO as compared to baseline (that is, post-DFO minus pre-DFO aluminum level) [12, 16] .
Bone biopsy. A standard technique previously reported was used in our study [17] . Briefly, double-tetracycline labeling with two short courses of two different tetracyclines (tetracycline and demeclocycline), separated by an interval of 17 days, was given to all study patients prior to bone biopsy, An iliac crest bone biopsy was obtained four to 10 days after the last dose of demeclocycline. All biopsies were fixed in 10% neutral phosphate-buffered formalin for 24 hours and then transferred to 70% ethanol. Undecalcified sections of trabecular bone were stained by the Goldner method [17, 18] , by aurin-tricarboxylic acid for detection of aluminum [18] , and by prussian blue for iron staining.
Class jfication of renal bone lesions The following histologic classification used in this study had been detailed previously [18] : (i) aplastic lesion (bone formation rate (BFR) < 108 jsm2/mm2/day; osteoid area (OA) < 15%; and fibrosis < 0.5%); (ii) osteomalacia (BFR < 108 sm2/mm2/day; OA 15%; and fibrosis < 0.5%); (iii) mild lesion (BFR 108 sm2/mm2/day; OA < 15%; and fibrosis < 0.5%); (iv) osteitis fibrosa (OF) (BFR 108 m2/mm2/day; OA < 15%; and fibrosis 5%); (v) mixed lesion (Mx) (BFR 108 m2/mm2/day; OA 15%; and fibrosis 0.5%).
Four bone disorder groupings used in this study have been previously defined [12] : (1) Aluminum bone disease (ABD) was defined as all cases of aplastic lesion or osteomalacia with SBSA 25%. In addition, mild and mixed lesions with SBSA 25% and "normal" BFR (108 <BFR < 250 sm2/mm2/day) were also defined as "transitional" lesions related to aluminum intoxication and were included as aluminum bone disease [19] . (2) Osteitis fibrosa and mixed lesions (OF/Mx) (with stainable bone surface aluminum (SBSA) < 25%) were combined into a single grouping of high-turnover bone disorders. (3) The mild Abbreviations are: OF, osteitis fibrosa; OM, osteomalacia. All cases of mixed and mild disorders with stainable bone surface aluminum 25% and "normal" bone formation rates between 108 and 250 m2/mm2/day were defined as aluminum bone disease (see Methods for details).
disorder was defined histologically as above, but in addition all cases had SBSA < 25%. (4) All cases of the aplastic lesions with SBSA < 25% were categorized as the aplastic (APL) disorder. The term "disorder" is used in this clinico-pathophysiologic classification to avoid any confusion with the above histologic classification (Table 1) , and does not necessarily imply a "disease" state. Finally, any case that did not fit into the above categories was classified as indeterminate.
Study patients Four hundred and forty-five of all the "current" as well as new patients entering the ESRD program in the study centers between October 1, 1987 and June 30, 1988 were assessed serially with a minimal follow-up of one year during the study. All patients were managed using a standardized protocol, and were dialyzed with solutions containing a calcium concentration of 6.5 or 7 mg/dl (1.625 or 1.75 mmol/liter). At the termination of our study, 268 patients (60% of the total population) underwent the above special investigations. Two hundred forty-eight of these patients were randomly selected and the other twenty were referred because of their clinical findings of bone disease. Deferoxamine test and/or bone biopsy specimens were lost in four of the 268 patients; in five other patients, biopsy specimens were inadequate for a pathologic diagnosis. To simplify the data analysis, three patients with bone disorders other than the above were further excluded (two with an indeterminate diagnosis and one with osteomalacia unrelated to aluminum intoxication). Thus, 256 patients were examined in this study.
All the study patients gave informed consent after a full explanation of the details, procedures, and potential risks of the study. The research protocol and consent form were approved by the institutional review board of the University of Toronto.
Statistical methods All data are expressed as means SEM, or percent. Univariate comparisons were made for various demographic and risk factors, and clinical and laboratory findings for diabetic and non-diabetic patients. Statistical testing for hypothesis generation was only performed on these parameters using unpaired t-test for continuous variables, and chi-square test (or Fisher's [20, 21] . If the continuous variables were skewed, the analysis was performed using data transformed by natural logarithms. All P-values reported are two-tailed. In a multivariant analysis, we have previously shown that cumulative dose of aluminum gels ingested since dialysis was a major risk factor for aluminum bone disease [11] .
In this study, we examined the relationship between the cumulative aluminum dose and diabetes mellitus on the probability of aluminum bone disease using logistic regression analysis [22] . All tests were performed using the SAS computer program [23] . 
Results

0
Patient characteristics Forty-five percent of the study patients were on hemodialysis, another 45% were on continuous ambulatory peritoneal dialysis (CAPD), and 10% were on intermittent peritoneal dialysis (IPD). Their demographics and risk factors for bone disease by diabetic status are shown in Table 2 . There were no significant differences between the insulin-dependent and noninsulin dependent diabetic patients with respect to their risk factors, and clinical and laboratory parameters except for their age (53 2.1 vs. 64 1.8, P < 0.0001). Thus, they were combined into a single group. Overall, 25% of the patients were diabetic. They were on dialysis for a shorter duration, had a lower cumulative exposure to aluminum gels, and used calcium carbonate as the only phosphate binder more frequently than the non-diabetic patients. Table 3 shows the clinical and laboratory findings of the diabetic and non-diabetic patients. There were no significant differences except for lower parathyroid hormone levels in the diabetic patients.
Bone disorders in the diabetic patients
Overall, 61% (157 of 256) of our patients were found to have a low-turnover bone disorder on biopsy. Within this group, 44% (69 of 157) had aluminum bone disease, and the remainder, the aplastic (or "adynamic") disorder. High-turnover bone disorders (that is osteitis fibrosa and the mixed disorder) were distinctly uncommon while the mild and the aplastic disorders tended to be more common in diabetic as compared to nondiabetic patients (Fig. 1) . The prevalence of aluminum bone disease was the same in both groups. The mean (± SEM) stainable bone surface aluminum in patients with the aplastic disorder was not different from that in patients with the mild Fig. 1 . Prevalence of bone disorders in patients with (gray bar) and without diabetes mellitus (white bar). High-turnover bone disorders [that is, osteitis fibrosa and mixed disorder (OF/Mx)] were distinctly uncommon (8 vs. 33%; P < 0.01 by Fisher's exact test), while the mild (19 vs. 9%; P = NS) and the aplastic (APL) disorders (with mean SEM stainable bone surface aluminum of 6.5 0.7%) (46 vs. 31%; P = NS) tended to be more common in diabetic patients. The prevalence of aluminum bone disease (ABD) was the same in both groups (27%). All P-values reported are two-tailed and Bonferroni-adjusted for multiple comparisons. disorder (6.5 0.7 vs. 6.3
1.0%), and yet their bone formation rates were significantly depressed. Selected bone morphometric parameters for each specific bone disorders in both diabetic and non-diabetic patients are shown in Table 4 . There were no differences in these parameters except in patients with aluminum bone disease where diabetic patients had lower bone formation rates than non-diabetic patients despite similar degrees of stainable bone surface aluminum.
Diabetes mellitus as a risk factor for aluminum bone disease We compared the aluminum exposure and burden in both diabetic and non-diabetic patients with aluminum bone disease ( aluminum bone disease ingested the same daily dose of aluminum gels as non-diabetic patients with aluminum bone disease. However, they were on dialysis for a shorter duration; thus, their cumulative exposure to aluminum gels was significantly less than that in non-diabetic patients. Nevertheless, the aluminum burden as assessed by delta aluminum post-deferoxamine infusion and by the percentage of stainable surface aluminum on bone biopsy was not different between the two groups. In addition, the average rate of aluminum accumulation on bone surfaces in diabetic patients was 50% higher than non-diabetic patients. Logistic regression analysis showed that the cumulative dose of aluminum gels ingested since dialysis was the major risk factor for aluminum bone disease (P < 0.000 1), but diabetes Fig. 2 . Probability of aluminum bone disease [P(ABD)J in diabetic and non-diabetic patients adjusted for the cumulative exposure of aluminum gels (ALUDOSE) ingested since dialysis (data expressed as predictive value and 95% confidence intervals). The risk of aluminum bone disease for diabetic patients was significantly higher, and doubled that of non-diabetic patients once a threshold of 3 kg of aluminum gels was ingested. In absolute terms, for example, there is a 50% probability for a diabetic patient who ingested 3 kg of aluminum gels to develop aluminum bone disease as compared to a 23% risk in a non-diabetic patient. Conversely, for a non-diabetic patient, ingestion of 8 kg of aluminum gels would be required to develop the same risk as the above diabetic patient. mellitus also interacted positively to increase this risk (P < 0.05). Figure 2 shows the probability of aluminum bone disease by diabetic status adjusted for the cumulative exposure of aluminum gels ingested. When the cumulative dose of aluminum gels was 3 kg or more, the probability for aluminum bone disease doubled in diabetic patients as compared to nondiabetic patients.
Discussion
We found that low-turnover bone disorders were the most common forms of osteodystrophy, occurring in 61% of our patients [11] [12] [13] . Within this group of disorders, aluminum bone disease accounted for 44%, and the aplastic disorder, the remainder. In contrast, the finding of the aplastic disorder as defined in our study with minimal or no stainable bone surface aluminum was distinctively uncommon in previous studies of uremic osteodystrophy [24-281. Thus, the emergence of this disorder as the single most common finding in our patients was most unexpected. In addition, we found that diabetes mellitus was an independent risk factor for both aluminum bone disease and the aplastic bone disorder [11] .
In this study, we found that diabetic patients ingested a significantly less cumulative dose of aluminum gels than nondiabetic patients. Nevertheless, the prevalence of aluminum bone disease was the same in both groups, raising the possibility that diabetic patients might be more prone to aluminum intoxication. Indeed, the risk of aluminum bone disease for diabetic patients was significantly higher, and doubled that of non-diabetic patients once a threshold of 3 kg of aluminum gels was ingested (Fig. 2) . In absolute terms, for example, there is a 50% probability for a diabetic patient who ingested 3 kg of aluminum gels (that is, over 2.5 years assuming a daily dose of 3.4 g) to develop aluminum bone disease as compared to a 23% risk in a non-diabetic patient. Conversely, a non-diabetic patient would have to ingest 8 kg of aluminum gels to develop the same risk as the above diabetic patient.
We also examined the aluminum burden in our patients by delta aluminum post-DFO infusion and by the percentage of stainable surface aluminum on bone biopsy and found that they were not different between the two groups. However, the rate of accumulation of aluminum on bone surfaces in diabetic patients was 50% higher than in non-diabetic patients. These findings suggest the possibility that in diabetic patients gastrointestinal absorption of aluminum may be enhanced. In addition, the low-turnover state such as the aplastic disorder in diabetic patients may also enhance aluminum accumulation in the bone as suggested previously [291. Finally, in patients with aluminum bone disease, diabetic patients had a more depressed bone formation rate than non-diabetic patients, suggesting that the modulating effect on bone turnover by aluminum intoxication and diabetes mellitus may be additive.
Although the pathogenesis of the aplastic disorder defined in this study remains unclear [30, 31] , we propose that it is not related to aluminum intoxication. Despite its histologic similarity to the aplastic lesion seen in aluminum intoxication, there was no evidence of significant aluminum overload in our patients with this disorder as assessed by the cumulative dose of aluminum gels ingested since dialysis, the deferoxamine test results, and the stainable surface aluminum on bone biopsy [11] . Comparing with the mild disorder, patients with the aplastic disorder had the same degree of stainable bone surface aluminum, and yet their bone formation rates were depressed (Table 4) . Thus, aluminum intoxication is unlikely to play an important role in the low-turnover state of this disorder. Recently, a bovine parathyroid cell culture study suggests that glucose and insulin may be independent modulating factors for parathyroid function. Hyperglycemia and insulin deficiency both inhibit parathyroid hormone release, and appear to interact synergistically [32] . Furthermore, insulin treatment has been shown to normalize the low parathyroid hormone levels and bone formation rates in diabetic rats [33] . Given all these findings, we believe that the diabetic state is an important factor that may reduce bone turnover in dialysis patients through modulation of parathyroid function [11] . Other potential factors which have been implicated to predispose to a bone lowturnover state include vitamin D treatment, parathyroidectomy, corticosteroid therapy and immobilization [30] . However, they did not appear to be important in our study. The clinical significance of the aplastic disorder remains unclear at the present time, since the follow-up of patients with this disorder is relatively short.
In conclusion, diabetes mellitus appears to be an important risk factor for both aluminum bone disease and the aplastic bone disorder possibly through modulation of parathyroid function. Chronic aluminum exposure is the most important factor for the development of aluminum bone disease, and diabetes mellitus enhances this risk significantly, possibly by increasing gastrointestinal absorption and bone surface accumulation of aluminum. Thus, oral ingestion of aluminum-containing medications (that is aluminum gels and sulcrafate) in diabetic patients should be strictly eliminated if possible. The aplastic disorder, seen in one-third of our patients, appears to be a novel finding. Further studies are needed to define the clinical significance of this disorder in diabetic patients.
